Literature DB >> 12655161

Risk stratification for asymptomatic patients with Brugada syndrome.

Hiroshi Morita1, Shiho Takenaka-Morita, Kengo Fukushima-Kusano, Makoto Kobayashi, Satoshi Nagase, Mikio Kakishita, Kazufumi Nakamura, Tetsuro Emori, Hiromi Matsubara, Tohru Ohe.   

Abstract

Ventricular fibrillation (VF) is induced in some asymptomatic patients with Brugada syndrome (BS), but the prognostic value of programmed electrical stimulation (PES) in such patients is controversial. The clinical characteristics of 41 asymptomatic BS patients, divided into 2 groups according to whether VF was induced by PES (inducible VF group: n=13, non-inducible VF group: n=28) were evaluated. ST levels in the right precordial leads were measured before and after administration of pilsicainide and the abnormal late potential (LP) was evaluated on the signal-averaged electrogram. The ST level at V(2) at baseline in the inducible VF group was significantly higher than that in the non-inducible VF group (p<0.05). Pilsicainide induced significant ST segment elevation in both groups and the ST level after pilsicainide in the inducible VF group was higher than that in the non-inducible VF group (p<0.01). LP was more frequent in the inducible VF group than in the non-inducible VF group. The criterion of ST level >0.15 mV at baseline with pilsicainide-induced additional ST elevation >0.10 mV and positive LP showed high sensitivity (92%) and specificity (89%) for detection of PES-induced VF in asymptomatic BS patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12655161     DOI: 10.1253/circj.67.312

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  10 in total

1.  Sodium channel blockers enhance the temporal QT interval variability in the right precordial leads in Brugada syndrome.

Authors:  Tetsuzou Kanemori; Hiroki Shimizu; Katsumi Oka; Yoshio Furukawa; Kenji Hiromoto; Takanao Mine; Tohru Masuyama; Mitsumasa Ohyanagi
Journal:  Ann Noninvasive Electrocardiol       Date:  2008-01       Impact factor: 1.468

2.  Positive Brugada challenge test in V1 R-V3 R as a predictor of malignant prognosis in Brugada patients.

Authors:  Arash Hashemi; Shahab Shahrzad; Sorayya Shahrzad; Siamak Saber; Samira Taban; Amir Aslani; Zahra Emkanjoo
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-05-03       Impact factor: 1.468

3.  Gender modulates the aging effects on different patterns of early repolarization.

Authors:  Yen-Chou Chen; Jen-Hung Huang; Yung-Kuo Lin; Ming-Hsiung Hsieh; Yi-Jen Chen
Journal:  Heart Vessels       Date:  2013-04-24       Impact factor: 2.037

4.  The pathophysiological mechanism underlying Brugada syndrome: depolarization versus repolarization.

Authors:  Arthur A M Wilde; Pieter G Postema; José M Di Diego; Sami Viskin; Hiroshi Morita; Jeffrey M Fish; Charles Antzelevitch
Journal:  J Mol Cell Cardiol       Date:  2010-07-24       Impact factor: 5.000

Review 5.  Brugada syndrome.

Authors:  Charles Antzelevitch
Journal:  Pacing Clin Electrophysiol       Date:  2006-10       Impact factor: 1.976

Review 6.  Brugada syndrome: from cell to bedside.

Authors:  Charles Antzelevitch; Pedro Brugada; Josep Brugada; Ramon Brugada
Journal:  Curr Probl Cardiol       Date:  2005-01       Impact factor: 5.200

7.  Brugada syndrome: Controversies in Risk stratification and Management.

Authors:  Lm Nunn; J Bhar-Amato; Pd Lambiase
Journal:  Indian Pacing Electrophysiol J       Date:  2010-09-05

Review 8.  Brugada syndrome: recent advances and controversies.

Authors:  Charles Antzelevitch; Eyal Nof
Journal:  Curr Cardiol Rep       Date:  2008-09       Impact factor: 2.931

9.  Anaesthetic management of a patient of Brugada syndrome for an emergency appendicectomy.

Authors:  Chetankumar Raval; Kiran Saeed
Journal:  Anesth Essays Res       Date:  2012 Jan-Jun

10.  Prognostic Significance of the Sodium Channel Blocker Test in Patients With Brugada Syndrome.

Authors:  Akira Ueoka; Hiroshi Morita; Atsuyuki Watanabe; Yoshimasa Morimoto; Satoshi Kawada; Motomi Tachibana; Masakazu Miyamoto; Koji Nakagawa; Nobuhiro Nishii; Hiroshi Ito
Journal:  J Am Heart Assoc       Date:  2018-05-10       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.